| Mackenzie Jones, MOT, OTR/L | |
|
4500 E Cherry Creek South Dr Ste 710, Denver, CO 80246-1534 | |
| (303) 432-8487 | |
| Not Available |
| Full Name | Mackenzie Jones |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 4500 E Cherry Creek South Dr Ste 710, Denver, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326506577 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.0005852 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mackenzie Jones, MOT, OTR/L 8390 Yarrow St, Arvada, CO 80005-2525 Ph: (816) 665-2173 | Mackenzie Jones, MOT, OTR/L 4500 E Cherry Creek South Dr Ste 710, Denver, CO 80246-1534 Ph: (303) 432-8487 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke.
Radio Australia examines the Global Fund to Fight AIDS, Tuberculosis and Malaria's push for more funding from Australia and China. Global Fund Executive Director "Michel Kazatchkine is currently touring the world's capitals seeking renewed government pledges to build on an already impressive record and as well as looking to Australia to do more, he's hoping soon to get China to become not just recipient, but donor."
In a recent study conducted at the Indian Institute of Science Education and Research, India, a team of scientists screened specific genes of SARS-CoV-2 to identify factors that may contribute to viral infectivity.
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
› Verified 9 days ago
Kristin Turner, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3105 W Arkansas Ave, Denver, CO 80219 Phone: 303-936-3497 | |
American Council For Th Eblind And Visually Impaired Of Colorado Acbco Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 910 16th St Ste 1240, Denver, CO 80202 Phone: 303-831-0117 Fax: 303-454-3378 | |
Ana Nicole Miller, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2979 Uinta St, Denver, CO 80238 Phone: 720-787-7800 | |
Melanie Marie Shovlin, MS, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1460 S Saint Paul St, Denver, CO 80210 Phone: 303-550-5868 | |
Kristen Dorighi, MS, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1667 S Lafayette St, Denver, CO 80210 Phone: 303-715-4482 | |
Sarah Whitaker, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6060 E Iliff Ave, Denver, CO 80222 Phone: 303-759-4221 | |
Julie Brahen, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2201 N Downing St, Denver, CO 80205 Phone: 303-861-4825 |